Results 181 to 190 of about 7,676,849 (387)

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Advancing Pediatric Patient-Reported Outcome Assessment [PDF]

, 2013
Forrest, Christopher B.
core   +1 more source

Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus studyResearch in context

EClinicalMedicine
Summary: Background: Chimeric Antigen Receptor (CAR) T-cell therapies are effective for treating haematological cancers but carry risks of toxicity and substantial symptom burden.
Sarah E. Hughes, Foram Khatsuria, Christel McMullan, Karen L. Shaw, Anita Walker, Francesca Kinsella, David Burns, Olalekan L. Aiyegbusi, Elin Haf Davies, John Ansell, Evelyn Chakera, Charles Craddock, Alastair Denniston, Rebecca Lloyd, Paul Ferguson, Ronjon Chakraverty, Melanie Calvert   +16 more
doaj  

The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Journal of Clinical Epidemiology, 2010
D. Cella, William T. Riley, A. Stone, N. Rothrock, B. Reeve, S. Yount, D. Amtmann, R. Bode, Daniel J Buysse, Seung W. Choi, K. Cook, R. Devellis, D. DeWalt, J. Fries, R. Gershon, E. Hahn, J. Lai, P. Pilkonis, D. Revicki, M. Rose, K. Weinfurt, R. Hays   +21 more
semanticscholar   +1 more source

Digitization of Patient-Reported Outcomes [PDF]

Value in Health, 2013
openaire   +3 more sources

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Quality of life after idiopathic multicentric Castleman disease in China: a cross-sectional, multi-center survey of patient reported outcome and caregiver reported outcome

Orphanet Journal of Rare Diseases
The majority of multicentric Castleman disease (MCD) patients in China are of the idiopathic subtype (iMCD) with systemic manifestations. However, the impact of iMCD on life quality, mental and psychological status, social function, and caregiving burden
Jia Chen, Miao-yan Zhang, Yu-han Gao, Lu Zhang, Jian Li   +4 more
doaj   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Development and validation of clinical implementation methods for patient-reported outcomes in Japanese multi-center palliative care units

Journal of Patient-Reported Outcomes
Background Patient-Reported Outcomes (PROs) are recommended for use in clinical oncology. However, they are not routinely used in professional palliative care practices in Japan.
Nao Ito, Azusa Sato, Kana Takeuchi, Tomoko Shigeno, Hiroko Sasaki, Maho Aoyama, Mitsunori Miyashita   +6 more
doaj   +1 more source